Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: A cooperative multinational trial

Annals of Oncology

Volumn 13, Issue 10, 2002, Pages 1539-1549

  Rosell, Rafael ^a   Gatzemeier, U ^b   Betticher, D C ^c   Keppler, U ^d   Macha, H N ^e   Pirker, R ^f   Berthet, P ^g   Breau, J L ^h   Lianes, P ⁱ   Nicholson, M ^j   Ardizzoni, A ^k   Chemaissani, A ^l   Bogaerts, J ^m   Gallant, G ^m  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b KRANKENHAUS GROSSHANSDORF   (Germany)

^c UNIVERSITY OF BERN   (Switzerland)

^d Fachklinik für Lungenkrankheiten   (Germany)

^e LUNGENKLINIK HEMER   (Germany)

^f UNIVERSITY OF VIENNA   (Austria)

^g CENTRE FRANÇOIS BACLESSE   (France)

^h AVICENNE HOSPITAL   (France)

ⁱ HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^j ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^k UNIVERSITY OF GENOA   (Italy)

^l Lungenklinik Merheim   (Germany)

^m BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

Carboplatin; Cisplatin; Doublets; Non small cell lung cancer; Paclitaxel

Indexed keywords

CARBOPLATIN; CIMETIDINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GRANISETRON; IFOSFAMIDE; LOMUSTINE; LORAZEPAM; METHOTREXATE; MITOMYCIN C; NAVELBINE; ONDANSETRON; PACLITAXEL; VINBLASTINE; VINDESINE;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC DISEASE; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA AND VOMITING; NEPHROTOXICITY; OTOTOXICITY; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; QUALITY OF LIFE; SURVIVAL;

EID: 0036810227     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf332     Document Type: Article

References (29)

1. Klastersky J, Sculier JP, Lacroix H et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for research and treatment of cancer protocol 07861. J Clin Oncol 1990; 8: 1556-1562.
2. Gatzemeier U, von Pawel J, Gottfried M et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2000; 18: 3390-3399.
3. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311: 899-909.
4. Cullen MH, Billingham LJ, Woodroffe CM et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999; 17: 3188-3194.
5. Breathnach OS, Freidlin B, Conley B et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 2001; 19: 1734-1742.
6. Crawford J, O'Rourke M, Schiller JH et al. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. J Clin Oncol 1996; 14: 2774-2784.
7. Ranson M, Davidson N, Nicolson M et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000; 92: 1074-1080.
8. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991; 9: 1618-1626.
9. Paesmans M, Sculier JP, Libert P et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. J Clin Oncol 1995; 13: 1221-1230.
10. Hickish TF, Smith IE, Ashley S, Middleton G. Chemotherapy for elderly patients with lung cancer. Lancet 1995; 346: 580.
11. Murphy WK, Fossella FV, Win RJ et al. Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993; 85: 384-388.
12. Chang AY, Kim K, Glick J et al. Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993; 85: 388-394.
13. Johnson DH, Paul DM, Hande KR et al. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 1996; 14: 2054-2060.
14. Langer CJ, Leighton JC, Comis RL et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995; 13: 1860-1870.
15. Bonomi P, Kim KM, Fairclough D et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000; 18: 623-631.
16. Giaccone G, Splinter TAW, Debruyne Ch et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. J Clin Oncol 1998; 16: 2133-2141.
17. Kelly K, Pan Z, Murphy J et al. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer. Clin Cancer Res 1997; 3: 1117-1123.
18. 2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Ann Oncol 2000; 11: 799-805.
19. Kelly K, Crowley J, Bunn PA et al. A randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19: 3210-3218.
20. Shyr Y, Choy H, Cmelak A et al. Pattern of practice survey: non-small cell lung cancer in the U.S. Proc Am Soc Clin Oncol 1998; 17: 463a (Abstr 1778).
21. Pocock S, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975; 31: 103-115.
22. Aaronson NK, Ahmedzai S, Bergman B et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
23. Bergman B, Aaronson NK, Ahmedzai S et al. The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 1994; 30A: 635-642.
24. ICH E9 Guideline: Statistical Principles for Clinical Trials, EU: CPMP/ICH/363/96, FDA: Federal Register, Vol. 63, No. 179, September 16, 1998, p. 49583.
25. Bonomi PD, Finkelstein DM, Ruckdeschel JC et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989; 7: 1602-1613.
26. The ICON Collaborators. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. Lancet 1998; 352: 1571-1576.
27. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
28. Rodriguez J, Pawel A, Pluzanska A et al. A multicenter, randomized phase III study of docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCB) vs vinorelbine + cisplatin (VC) in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer. Proc Am Soc Clin Oncol 2001; 20: 314a (Abstr 1252).
29. Georgoulias V, Papadakis E, Alexopoulos A et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 2001; 357: 1478-1484.